Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature-Reference-Cited by-同舟云学术

Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature

Published:2016-02 Issue:2 Volume:195 Page:254-263
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Oing Christoph¹²,Rink Michael¹²,Oechsle Karin¹²,Seidel Christoph¹²,von Amsberg Gunhild¹²,Bokemeyer Carsten¹²

Affiliation:

1. Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Eppendorf, Hamburg, Germany

2. Department of Urology (MR), University Medical Center Eppendorf, Hamburg, Germany

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference49 articles.

1. Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls;Bellmunt;Ann Oncol,2011

2. Second-line chemotherapy for advanced urothelial cancer: because we should or because we can?;Dreicer;J Clin Oncol,2009

3. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract;Bellmunt;J Clin Oncol,2009

4. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma;McCaffrey;J Clin Oncol,1997

5. A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma;Kim;J Clin Oncol,2013

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study;Clinical Genitourinary Cancer;2024-10

2. Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021;Clinical Genitourinary Cancer;2024-06

3. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment;International Journal of Molecular Sciences;2024-05-17

4. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan;Journal of Cancer Research and Clinical Oncology;2024-04-09

5. Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy;Pharmaceutical Research;2024-02-17